Skip to main content

Table 3 Summary of AEs by current treatment group

From: Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry

AE category

nsNSAID (n = 225a) n (%)

Celecoxib (n = 68a) n (%)

Off NSAIDb(n = 79) n (%)

Patients with at least 1 AE

117 (52.0)

36 (52.9)

37 (46.8)

Patients with at least 1 AE causing temporary discontinuation

14 (6.2)

7 (10.3)

2 (2.5)

Patients with at least 1 serious AE

9 (4.0)

2 (2.9)

3 (3.8)

Patients with at least 1 AE of special interest

2 (0.9)

0

2 (2.5)

Patients with at least 1 GI composite eventc

73 (32.4)

23 (33.8)

17 (21.5)

  1. aPatients who switch treatments contribute to both treatment groups.
  2. bOff NSAID is defined as 29 or more days after last dose of final study medication.
  3. cNausea/vomiting, abdominal pain, or all other GI.
  4. Abbreviations: AE Adverse event, GI Gastrointestinal, nsNSAID Nonselective nonsteroidal anti-inflammatory drug.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096